This book will present contributions by economists, systems developers, safety, health services, occupational and environmental health, and biomedical researchers in the fields of regulatory development, safety, quality assurance, health outcomes, occupational health, and biomedicine. The contributing research will explore the synergy of new science-based risk regulatory approaches, industry focus on manufacturing efficiencies and information technology and biogenetic innovations, and consumers demand for improved safety and quality of products, services, quality assurance, and transparency of information.The book investigates the impact of information technology, biogenetic, and pharmacological innovation on individuals quality of life, safety, individual and system health care utilization, occupational and environmental health and formulary decision making, and costs. It contains analyses of clinical and health outcomes resulting from innovative biopharmaceutical entities and delivery systems in the treatment of chronic conditions. It emphasises effective quality, regulatory system, and consistent science-based decision-making practices from private and public organizations and demonstrates regulatory issues affecting innovation and efficiency.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
This book will present contributions by economists, systems developers, safety, health services, occupational and environmental health, and biomedical researchers in the fields of regulatory development, safety, quality assurance, health outcomes, occupational health, and biomedicine. The contributing research will explore the synergy of new science-based risk regulatory approaches, industry focus on manufacturing efficiencies and information technology and biogenetic innovations, and consumers demand for improved safety and quality of products, services, quality assurance, and transparency of information. The book investigates the impact of information technology, biogenetic, and pharmacological innovation on individuals quality of life, safety, individual and system health care utilization, occupational and environmental health and formulary decision-making, and costs
*Contains analyses of clinical and health outcomes resulting from innovative biopharmaceutical entities and delivery systems in the treatment of chronic conditions
*Emphasises effective quality, regulatory system, and consistent science-based decision-making practices from private and public organizations
*Demonstrates regulatory issues affecting innovation and efficiency
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Basi6 International, Irving, TX, Etats-Unis
Etat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. N° de réf. du vendeur ABEOCT25-115111
Quantité disponible : 1 disponible(s)
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 4908464-n
Quantité disponible : 15 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9780762313464_new
Quantité disponible : Plus de 20 disponibles
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L1-9780762313464
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : New. N° de réf. du vendeur 4908464-n
Quantité disponible : Plus de 20 disponibles
Vendeur : Rarewaves USA, OSWEGO, IL, Etats-Unis
Hardback. Etat : New. This book will present contributions by economists, systems developers, safety, health services, occupational and environmental health, and biomedical researchers in the fields of regulatory development, safety, quality assurance, health outcomes, occupational health, and biomedicine. The contributing research will explore the synergy of new science-based risk regulatory approaches, industry focus on manufacturing efficiencies and information technology and biogenetic innovations, and consumers demand for improved safety and quality of products, services, quality assurance, and transparency of information.The book investigates the impact of information technology, biogenetic, and pharmacological innovation on individuals quality of life, safety, individual and system health care utilization, occupational and environmental health and formulary decision making, and costs. It contains analyses of clinical and health outcomes resulting from innovative biopharmaceutical entities and delivery systems in the treatment of chronic conditions. It emphasises effective quality, regulatory system, and consistent science-based decision-making practices from private and public organizations and demonstrates regulatory issues affecting innovation and efficiency. N° de réf. du vendeur LU-9780762313464
Quantité disponible : Plus de 20 disponibles
Vendeur : Rarewaves.com USA, London, LONDO, Royaume-Uni
Hardback. Etat : New. This book will present contributions by economists, systems developers, safety, health services, occupational and environmental health, and biomedical researchers in the fields of regulatory development, safety, quality assurance, health outcomes, occupational health, and biomedicine. The contributing research will explore the synergy of new science-based risk regulatory approaches, industry focus on manufacturing efficiencies and information technology and biogenetic innovations, and consumers demand for improved safety and quality of products, services, quality assurance, and transparency of information.The book investigates the impact of information technology, biogenetic, and pharmacological innovation on individuals quality of life, safety, individual and system health care utilization, occupational and environmental health and formulary decision making, and costs. It contains analyses of clinical and health outcomes resulting from innovative biopharmaceutical entities and delivery systems in the treatment of chronic conditions. It emphasises effective quality, regulatory system, and consistent science-based decision-making practices from private and public organizations and demonstrates regulatory issues affecting innovation and efficiency. N° de réf. du vendeur LU-9780762313464
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 4908464
Quantité disponible : Plus de 20 disponibles
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Hardcover. Etat : Like New. Like New. book. N° de réf. du vendeur ERICA77307623134636
Quantité disponible : 1 disponible(s)
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Hardback. Etat : New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days. N° de réf. du vendeur C9780762313464
Quantité disponible : Plus de 20 disponibles